Genprex (NASDAQ:GNPX) Stock Price Down 6% – Time to Sell?

Genprex (NASDAQ:GNPX) dropped 6% on Monday . The company traded as low as $6.72 and last traded at $7.21. Approximately 27,461 shares changed hands during trading, a decline of 10% from the average session volume of 30,610 shares. The stock had previously closed at $7.67.

Analyst Upgrades and Downgrades

GNPX has been the subject of several research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a report on Tuesday, April 21st. Wall Street Zen raised Genprex from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Genprex has an average rating of “Sell”.

Genprex Trading Down 6.0%

The firm’s 50 day simple moving average is $13.80 and its two-hundred day simple moving average is $31.41. The firm has a market cap of $3.68 million, a price-to-earnings ratio of -0.51 and a beta of -0.92.

Genprex (NASDAQ:GNPX) last announced its earnings results on Wednesday, May 13th. The company reported ($14.08) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Genprex

A number of hedge funds have recently added to or reduced their stakes in GNPX. Mayflower Financial Advisors LLC acquired a new position in Genprex in the 1st quarter valued at $36,000. Manchester Financial Inc. acquired a new stake in shares of Genprex during the 1st quarter worth $36,000. Finally, Susquehanna International Group LLP increased its position in shares of Genprex by 11.7% in the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock worth $58,000 after purchasing an additional 35,661 shares during the period. Institutional investors own 14.05% of the company’s stock.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.